Articles

CBA Members

Propriété
intellectuelle

Section du droit de la propriĂ©tĂ© intellectuelle de l’ABC

Les articles de la Section du droit de la propriĂ©tĂ© intellectuelle de l’ABC sont publiĂ©s par la Section du droit de la propriĂ©tĂ© intellectuelle. Les membres qui souhaitent proposer des articles sont invitĂ©s Ă  les envoyer Ă  la section Ă  : droitproprieteintellectuelleABC@cba.org.

AujourdÊŒhui
AujourdÊŒhui

Case summary: Court upholds Prothonotary’s decision that patent agent-client privilege subsists in communications made prior to Patent Act s. 16.1 coming into force

  • 25 fĂ©vrier 2021
  • David Schnittker

Distrimedic Inc. (“Distrimedic”), the Defendant in a patent infringement action, appealed an Order of Prothonotary Steele. That Order dismissed Distrimedic’s motion contesting the privilege asserted by Richards Packaging Inc. (“Richards”) over documents in its affidavit of documents. The Court dismissed Distrimedic’s appeal.

Propriété intellectuelle

Case summary: Appeal of first trial decision under amended Regulations dismissed

  • 25 fĂ©vrier 2021
  • Benjamin Pearson

The Appellants, Amgen Inc. and Amgen Canada Inc. (“Amgen”), appealed a decision of the Federal Court that found claims 43-47 of Canadian Patent No. 1,341,537 to be obvious. Amgen argued that the Federal Court committed a reviewable error in applying the test for obviousness.

Propriété intellectuelle

Case Summary: Federal Court upholds Prothonotary’s Order granting release of a settlement agreement in Pharmascience v Pfizer Canada ULC

  • 25 fĂ©vrier 2021
  • Kelly McClellan

The Federal Court dismissed Pharmascience’s appeal of a Prothonotary’s Order ordering Pfizer (i) to produce an unredacted settlement agreement between Pfizer and a third party, contingent on consent of the third party, and (ii) declining to order production of a second unredacted settlement agreement between the same parties (2, 3, 15).

Propriété intellectuelle

Case summary: Federal Court of Appeal clarifies the requirements for leave to appeal interlocutory orders made under the PM(NOC) Regulations

  • 25 fĂ©vrier 2021
  • Katie O’Meara

This decision concerned two motions for leave to appeal from a Prothonotary’s interlocutory order made under the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the “Regulations”) as amended. Apotex Inc was the Applicant and Allergen et al. was the Respondent on the first appeal. Pharmascience Inc was the Applicant and Bayer Inc et al was the Respondent on the second appeal.

Propriété intellectuelle

Case summary: Costs awarded to plaintiff following defendant’s discontinuance of counterclaim

  • 25 fĂ©vrier 2021
  • Hung Nguyen

The Plaintiff seeks costs, following the Defendant’s filing of a Notice of Discontinuance to discontinue their counterclaim. The Defendant argues that the Plaintiff is not entitled to costs because those costs were already addressed in a previous court Order, and also because the items in the Plaintiff’s Bill of Costs do not exist in the list of items provided in Tariff B of the Federal Courts Rules, SOR/98-106 (FCR).

Propriété intellectuelle

Case summary: Federal Court of Appeal denies a request for a cost variance

  • 25 fĂ©vrier 2021
  • Hung Nguyen

This matter concerns an assessment of costs pursuant to 1) a Judgment of the Federal Court of Appeal (the “FCA”), wherein the Appellant’s appeal from an Order of the Federal Court was “dismissed with costs, including the costs of preparation of the appeal book”; and 2) an Order of the FCA, wherein the Respondent was awarded costs in relation to the Appellant’s motion.

Propriété intellectuelle

RĂ©sumĂ© jurisprudentiel : La Cour d’appel fĂ©dĂ©rale rejette l’appel d’un jugement de la Cour fĂ©dĂ©rale sur des conclusions d’invaliditĂ© de trois brevets pour antĂ©rioritĂ© et Ă©vidence pour des inventions concernant les vĂ©hicules « tout-terrain » (VTT)

  • 25 fĂ©vrier 2021
  • Kelly McClellan

La Cour d’appel fĂ©dĂ©rale a rejetĂ© un appel d’un jugement de la Cour fĂ©dĂ©rale, notamment Camso Inc. c. Soucy International Inc., 2019 CF 255 (Raisons CF), qui a rejetĂ© une action concernant trois brevets, 2,388,294 (brevet ‘294), 2,828,509 (brevet ‘509), et 2,822,562 (brevet ‘562), parce que le juge a conclu que les revendications en litige dans chacun des trois brevets Ă©taient invalides pour l’antĂ©rioritĂ© et l’évidence (Raisons CAF, 1, 2, 6).

Propriété intellectuelle

Case summary: Filing of reply expert evidence

  • 25 fĂ©vrier 2021
  • Ken Clark and Lawrence Veregin

This decision concerns a motion by the Plaintiffs to seek leave to file reply expert reports from its expert witnesses in a patent impeachment action. The reply expert reports include the experts’ responses to new issues and a rebuttal to the Defendant’s expert’s claim construction based on correspondence with the patent office during prosecution of the patent (s. 53.1(1) of the Patent Act).

Propriété intellectuelle